Medicinehospital

Bevacizumab

An eye injection used to treat wet age-related macular degeneration.

Clinical information

Common uses

wet age-related macular degeneration (eye injection)

Common side effects

bleeding on the white of the eye

Cautions

eye infection or retinal detachment can occur after injection
eye pressure may rise shortly after injection
possible risk of blood clot events (VEGF inhibition)
not for use with eye infections

Pregnancy: only if clearly needed — may pose risk to the baby

Reference information, not medical advice — always follow your doctor or pharmacist. Source: DailyMed, dailymed.nlm.nih.gov, LYTENAVA (bevacizumab-vikg) label, setid 7f9a3014-b3d4-4943-a83a-92a77d8f947c (accessed 2026-08-16)

Approved brands & formulations5

Brand name	Dosage form	Strength	Importer	Category
Bevacizumab	Parenteral ( Injection )	100mg/4ml (25mg/ml)	MFDA designated importers with Pre Authorization approval before import	hospital
Bevacizumab	Tablet	300 mg	—	POM
Bevacizumab	Parenteral ( Injection )	400mg/16ml (25mg/ml)	MFDA designated importers with Pre Authorization approval before import	hospital
Versavo 100 mg/4 mL	Parenteral ( Concentrated for solution for infusion )	100 mg/4 mL	State Trading Organization Plc	hospital
Versavo 400mg/16mL	Parenteral ( Concentrated for solution for infusion )	400mg/16mL	State Trading Organization Plc	hospital